MB Therapeutics reaches a new milestone in its development by raising 2 million euros in its first seed round.

This funding, backed by strategic investors such as Beprep, Calyseed, Angels Santé, theBanque Populaire d'Investissement (BPI), as well as Business Angels expert in the field of pharmaceutical formulations like Sébastien Gallice, will allow the company to develop and launch the first industrial 3D printing solution for personalized medicines in pharmacies.

This new chapter allows MB Therapeutics to strengthen its position in the pharmacy market, introducing an innovative, turnkey solution for manufacturing personalized medications in pharmacies.

Towards a new era of personalized medicine

Today, standard treatments are increasingly tailored to the individual characteristics of patients. Thanks to 3D printing, MB Therapeutics is developing a technology that makes it possible to adjust the dosages, shapes, and compositions of medications according to the unique needs of each individual. This approach offers more effective and better-tolerated patient care, while reducing pharmaceutical waste.

With this fundraising, MB Therapeutics will achieve the following objectives:

• Intensify the development of pharmaceutical 3D printing technology.

• Continue developing production processes to transition to an industrial scale.

• Continue structuring the teams and recruiting new talent to support its growth.

• Establish strategic collaborations with laboratories, hospitals, and pharmaceutical industries.

An ambition for growth and leadership

With this fundraising, MB Therapeutics reinforces its ambition to become a key player in the field of personalized medicine. The start-up positions itself as the sole provider of industrial-grade 3D medicine printing solutions for pharmacies, a rapidly expanding sector estimated at 12 billion dollars with an annual growth rate of 7%.

The funds will allow MB Therapeutics to launch, in 2026, three highly demanded medications, while preparing a future funding round to support its international expansion and its role as a leader in custom medicine manufacturing.

MB Therapeutics, a magic project

Founded in 2023, MB Therapeutics has set itself the mission to develop innovative solutions for the pharmaceutical industry. At the origin of the project was a simple observation: patients are often faced with unsuitable medications, both in terms of dosage and release profile. With this in mind, Dr. Stéphane Roulon, engineer, and Dr. Ian Soulairol, hospital pharmacist at the Nîmes University Hospital, combined their expertise to create MB Therapeutics.

The company has developed a unique technology based on pharmaceutical inks, allowing the manufacture of personalized medicines directly in pharmacies. This innovation paves the way for tailor-made treatments, better suited to patient needs, while ensuring efficacy and safety.

With a vision focused on innovation and collaboration, MB Therapeutics surrounds itself with experts and strategic partners to accelerate the development and market launch of its solutions. Supported by key funding, the company continues its growth and actively contributes to the evolution of the pharmaceutical sector by bringing concrete, large-scale applicable advancements.

A few words from the MB team

This fundraising gives us the means to go further, faster, to position MB Therapeutics as a key player in the pharmacy of the future.

We warmly thank our investors, our partners, and our teams who make this adventure possible. It is thanks to this synergy that we can realize our vision and build a future where every patient benefits from a treatment perfectly suited to their needs. This is just the beginning of a great transformation.